- Key Insight: Discover how federal policy and pharma pricing are normalizing employer-funded IVF benefits.
- What’s at Stake: Employers risk recruitment and retention losses if benefits lag evolving reproductive expectations.
- Supporting Data: EMD Serono deal offers up to 84% discount off IVF therapy list prices.
- Source: Bullets generated by AI with editorial review
Benefit managers should take note of recent policy changes by the Trump administration aimed at making in vitro fertilization more affordable. It’s the latest validation that providing reproductive benefits is now table stakes.
